Sleep Apnea Drug Breakthrough, PFAS Water Alert, and a Malaria Vaccine Milestone

A GLP-1 drug halves sleep apnea, WHO flags PFAS in Mediterranean water, and a malaria vaccine holds 77% efficacy at three years.

• Tirzepatide Cuts Obstructive Sleep Apnea Severity in Half in Landmark Phase-3 Trial
• WHO Raises Global Alarm on PFAS in Drinking Water; Mediterranean Aquifers Among Regions Flagged
• Oxford's R21/Matrix-M Malaria Vaccine Sustains 77% Efficacy at Three-Year Follow-Up
• Novel Anti-Inflammatory Antibody Achieves 68% Remission in Treatment-Resistant Depression
• Oral Teplizumab Delays Type 1 Diabetes Onset by 5.4 Years in High-Risk Children
• ECDC and Cyprus MoH Issue Early-Autumn Influenza Vaccination Advisory